

3RD ANNUAL

2017
* BROCHURE *

biotechandmoney LONDON medtechandmoney LONDON

7 - 8 FEBRUARY 2017 | ETC. VENUES, 155 BISHOPSGATE | LONDON

525+
EXECUTIVES

100+
SPEAKERS

200+
INVESTORS

40+
SHOWCASES

BRINGING DEALS TO LIFE

biotechandmoney
LONDON

medtechandmoney
LONDON

HealthEx
CEO FORUM

MedtEx
CEO FORUM

Inv€stable

LEAD PARTNERS



PLATINUM PARTNER



GOLD PARTNERS



SILVER PARTNERS



WHITE & CASE

WELCOME

biotechandmoney
LONDON

medtechandmoney
LONDON

Dear Colleague,

We're delighted to bring you the 3rd annual Biotech and Money / Medtech and Money London conference.

With our relentless focus on quality peer-2-peer discussion, high level networking and partnering, unique formats and a vetted, high-calibre audience, we bring together the people that matter to the future of healthcare and life science funding, finance, investment and deal making.

For 2017 we're excited to announce a number of new additions to the content and formats that you are used to seeing at this flagship investment conference. It's a packed two days.

We've also expanded our international reach by bringing our US and EU network to bear on the programme, ensuring we garner the experience and best practice from around the globe.

Our mission remains one of delivering a conference of unparalleled seniority and relevance, providing you with the solutions to further your business needs in 2017.

Thank you for joining us and we wish you an incredible event.

Terence O'Dwyer
Co-CEO

Neil Darkes
Co-CEO

PS. Access onsite Wifi through the network **etcvenues** with password **wifi8027**

PPS. View the venue floor on page 22.

WHAT'S NEW IN 2017?

- **EXCLUSIVE LAUNCH OF LIFE SCIENCE INVESTOR PERCEPTION REPORT (P.3)**
- **LAUNCH OF CO-LOCATED MEDTEX CEO FORUM (P.4) AND MEDTECH CONFERENCE (P.11)**
- **40+ INV€\$TABLE SHOWCASE PRESENTATIONS FROM UK , US AND EUROPE'S FINEST PUBLIC AND PRIVATE BIOTECH AND MEDTECH COMPANIES (P.15)**
- **8 INDEPTH ROUNDTABLE DISCUSSIONS WITH REAL PRACTICAL OUTCOMES (P.4)**
- **MORE EUROPEAN AND US INVESTORS, COMPANIES AND PHARMA THAN EVER BEFORE**

WHAT MAKES US DIFFERENT



KEYNOTE PANELS WITH LEADING LIFE SCIENCE FUNDS

INSPIRATIONAL, THOUGHT PROVOKING AND HIGH LEVEL



PANEL DISCUSSIONS ON KEY LIFECYCLE AREAS

DEBATE AROUND SEED, EARLY AND GROWTH TACTICS



'ANATOMY OF...' CASE STUDY DISCUSSIONS

COMPARE AND CONTRAST THE APPROACHES OF SUCCESSFUL COMPANIES



BLUE SKY PLENARY 'OUTLOOK' SESSIONS

PROVIDING EXECUTIVE FORESIGHT FOR THE YEAR AHEAD



CHATHAM HOUSE RULE LISTED CEO FORUMS

PEER-TO-PEER DEBATE BETWEEN PUBLIC EXECS AND INVESTORS



A TRULY INTERNATIONAL CONFERENCE

PARTICIPATION FROM UK, EUROPE AND US



'INVESTABLE' SHOWCASE PRESENTATIONS

OVER 40 INNOVATIVE BIOTECH AND MEDTECH COMPANIES



EXHIBITION-FREE NETWORKING

DISTRACTION-FREE, HIGH LEVEL INTERACTIONS



PRE-EVENT ONLINE 1-2-1 PARTNERING SYSTEM

ARRANGE ONSITE MEETINGS AND DO BUSINESS IN PRIVATE

DAY ONE - TUESDAY 7TH FEBRUARY 2017

8.00

REGISTRATION AND BREAKFAST

BROADGATE SUITE

9.00

WELCOME REMARKS

Neil Darkes, Co-CEO, Biotech and Money

9.10

OPENING KEYNOTE PANEL: NEW BREEDS OF PATIENT AND CONSISTENT CAPITAL

In this high level discussion we assemble a panel of senior investment executives who will debate the key issues that will influence the future success and prosperity of the UK entrepreneurial finance ecosystem, including how the UK can ensure the stimulation, growth and innovation in the Life Science sector. Chiefly executives will represent the new breed of patient capital; consistent capital and how this approach can fill the current void.

Moderator: Clive Cookson, Science Editor, Financial Times

Jim Mellon, Co-Chairman and Founder, Mann Bioinvest

Nigel Pitchford, CIO, Touchstone Innovations

Martin Murphy, CEO, Syncona Partners

Kate Bingham, Managing Partner, SV Life Sciences

9.50

KEYNOTE PANEL: STATE OF THE NATION(S): UK, EU AND US CAPITAL FLOW

As the healthcare sector continues to develop favourably what can the UK and Europe be doing better (or more of) to see a more sustained or increased capital flow?. Prominent UK, EU and US venture fund Executives share the stage to outline their views and challenges of life science investment, plus share their views on institutional, family office and private investor appetite in the year ahead.

Moderator: Fiona Barry, Reporter, BioPharm Insight, Mergermarket Group

Tim Haines, Managing Partner, Abingworth

Sander Sloodweg, Managing Director, Forbion Capital Partners

Hubert Birner, Managing Partner, TVM Capital Life Science

Alex Pasteur, Partner, F-Prime Capital

Johnston Erwin, Vice President, Corporate Business Development, Eli Lilly & Co.

10.30

EXCLUSIVE LAUNCH OF BIOTECH AND MONEY INVESTOR PERCEPTION REPORT

The mission of this survey and report is to create unique and actionable insight into investor attitudes, biases and preferences in healthcare opportunities in Europe, that can be used by our community to inform their decisions and strategy.

This survey and report will hopefully address this gap in knowledge, while at the same time providing powerful insight that can be leveraged by key stakeholders for their own strategic decision making.

We are very proud to share it with you a summary of our findings.

Terry O'Dwyer, Co-CEO and Co-Founder, Biotech and Money

10.40

LOOKING BEYOND 'BEYOND BORDERS'

When do successful Biotechs start their operational journey? What can we draw from the US market to support the U.K. in stepping up in this space and why do investors reward operations?. These are just some of the themes to be discussed in this position piece by EY, as an extension the 2016 release of their Biotechnology report 'Beyond Borders'.

David MacMurchy, Head of Life Sciences, EY

11.00

MORNING REFRESHMENTS

ROUNDTABLES OR 1-2-1 PARTNERING

11.30

Join one of 8 roundtables on a specific strategic theme or Therapeutic area and join a 12-person, moderated discussion with practical outcomes. Limited places exist.

HOW TO GET THE MOST VALUE OUT OF YOUR IP

Isobel Finnie, UK & EU Patent Attorney

HASELTINE LAKE ^{LLP}
EUROPEAN PATENT AND TRADE MARK ATTORNEYS

HOW TO EQUITY CROWDFUND

Daniel Oliver, CEO

Capital Cell

HOW TO ACCESS DEBT FINANCE

Nooman Haque, Director of Healthcare & Life Sciences

svb

Silicon Valley Bank

HOW TO ATTRACT AND RETAIN TALENT

John Jakenfelds, Global Practice Leader for Life Sciences and Melanie West, Consultant



ODGERS BERNDTSON
Search Intelligence

PARTNERING IN NEUROSCIENCE

Jennifer Laird, Senior Director, Neuroscience Search & Evaluation

Lilly

AUTOIMMUNE DISEASES: FUTURE R&D

Adam Houghton, Senior Director & Head, Immunology Search & Evaluation

abbvie

INFECTIOUS DISEASE

Michel de Baar, Executive Director, Business Development, Early Stage S&E, Infectious Disease Europe

MSD

ADVANCED THERAPIES

Matthew Durdy, CBO

CATAPULT
Cell and Gene Therapy

1-2-1 PARTNERING



If the roundtables don't interest you, get a head start on your 1-2-1 partnering and use this 1hr 15mins session to lock in those all important face-to-face meetings.

If you've not pre-secured a table within the partnering room, meet at one of the three 'Buzz Stops' on the atrium floor for more informal conversations.

CEO FORUM

11.30

HealthEx MedtEx
CEO FORUM CEO FORUM

HealthEx CEO Forum is a biannual closed door, Chatham House Rule, invite only forum for CEOs, CFOs and Chairmen of listed and soon-to-be listed life science and healthcare companies.

This forum provides peer-to-peer review and open, honest and frank debate between like minded executives and a selection of prominent investors.

The forum will provide opportunities for executives to share their successes and debate the opportunities and obstacles that sit between them and their strategic ambitions.

You must be a **HEALTHEx** Badge Holder to access this forum.

The **first 1hr 15mins session** will provide a deep-dive into the results of the commissioned Investor survey and report.

Executives will be joined by a number of life science sector institutionals and cross-over funds to discuss the results in more detail, interrogate the data and provide conclusion notes.

Moderator:

Terry O'Dwyer, Co-CEO, Biotech and Money

12.45

NETWORKING LUNCH SUPPORTED BY



BRITISH
PHARMACOLOGICAL
SOCIETY

ROUNDTABLES

11.30

Specific Funding and Finance themed Roundtables

Max.12 persons per table. Seats are allocated first come, first served via online survey and onsite sign-up sheets. If spaces exist on the onsite sign-up sheets, add your name. You must be signed up to attend these sessions.

BROADGATE SUITE

TABLE 1: HOW TO GET THE MOST MOST VALUE OUT OF YOUR IP

Isobel Finnie, UK and EU Patent Attorney



- Creating an IP strategy to fit your business plan and ensuring your IP is due diligence ready
- The patentability/patent eligibility of biotech inventions is in flux: navigating this to have an internationally robust patenting strategy
- What you can do about conflicting third party patents

TABLE 2: HOW TO EQUITY CROWDFUND

Daniel Oliver, CEO



- Equity Crowdfunding is growing fast - it's set to overtake VC investment in the Eurozone by 2020. But how does it really work?
- Specialist-led crowdfunding platforms are already used to fund Pharma Series B in the US, and multi-million rounds are already happening in Europe
- Sector focused crowdfunding is starting to bring real value to Angels and proving to be the perfect complement to highly knowledgeable investors

TABLE 3: HOW TO ACCESS DEBT FINANCE

Nooman Haque, Director of Healthcare & Life Sciences



Debt finance has become an established way to support life science companies whilst preserving equity structures and assisting investors in their reserves strategy. This session will explore how and when to utilise debt finance in support of your R&D and early development. A session for life science companies that have at least raised a Series A from institutional investors and may still be in R&D/early commercial development.

A case-study table discussion led by the host and guided by participants focusing on the following key themes:

- Why is debt finance in life sciences R&D so much more prevalent in Europe and the US, but not in the UK?
- When are investors likely to support a debt facility?
- Learn about the benefits, challenges & structuring techniques of debt finance and when to utilise it for the maximum advantage

TABLE 4: HOW TO ATTRACT AND RETAIN TALENT

John Jakenfelds, Global Practice
Leader for Life Sciences and **Melaine West**, Consultant



It is estimated that 100+ leadership teams ("Growing the next generation of UK Management Talent" BIA, 2016) are required over the coming years to build and drive new biotech companies towards commercial success.

- What can be done/is being undertaken to actually solve this challenge in the near term?

12.45

NETWORKING LUNCH SUPPORTED BY



11.30

Specific Therapeutic area Roundtables

Max.12 persons per table. Seats are allocated first come, first served via online survey and onsite sign-up sheets. If spaces exist on the onsite sign-up sheets, add your name. You must be signed up to attend these sessions.

BROADGATE SUITE

**TABLE 5:
PARTNERING IN NEUROSCIENCE**

Jennifer Laird, Senior Director, Neuroscience S&E


Neurodegenerative Diseases

- Novel therapeutic approaches for disease modification in neurodegenerative diseases, especially Alzheimer's disease and Parkinson's disease
- Novel treatments that address the symptoms of neurodegenerative disease including psychosis, cognitive impairment, agitation, mood and sleep

Biomarkers

- Blood-based biomarkers for early detection of amyloid-positive dementia
- Wearable technologies and smartphone applications for early detection of Alzheimer's disease initiation and progression

Pain and Migraine

- Novel approaches to treat chronic neuropathic, inflammatory or visceral pain
- Migraine prophylaxis

**TABLE 7:
INFECTIOUS DISEASE**

Michel de Baar, Executive Director, Business Development, Early Stage Search & Evaluation, Infectious Disease Europe



Exploring the microbiome for new drugs and targets to provide new treatments for patients

- Can we apply conventional research approaches, clinical design and business models to develop a successful microbiome-biotech?
- How can biotech and big pharma collaborate to accelerate R&D within the microbiome field?
- How can we provide evidence of efficacy through a relatively undefined 'organ'?

**TABLE 6:
AUTOIMMUNE DISEASES: FUTURE R&D DIRECTIONS**

Adam Houghton, Senior Director & Head, Immunology S&E



- Remaining unmet needs in the disease areas of Rheumatology, Dermatology and Gastroenterology
- Future therapeutic targets and modalities – what can we leverage from R&D in the field of Immuno-Oncology?
- Can future therapies be “personalised” through the development of predictive biomarkers and diagnostics?

**TABLE 8:
ADVANCED THERAPIES**

Matthew Durdy, Chief Business Officer



Ways to reduce perceived risk and increase value ahead of seeking funding:

- Capital cost, control and IP preservation: alternatives strategies to contract management and “build your own factory”
- Cost of goods: planning for and integrating automation and other ways to address cost of goods concerns.
- Product design: product, pricing, service, reimbursement and preparing for competition.

12.45

NETWORKING LUNCH SUPPORTED BY


SEED / EARLY-STAGE

BROADGATE 1

1.45 Josh Dance, SVP,
Biotech and Money

1.45 Accelerating promising programs for VC and pharma

We invite UK and EU Tech Transfer Heads to discuss the innovative approaches being taken by the various offices and the roles they play, and the outcomes they are effecting to support early stage.

Moderator: Iain Thomas, Head of Life Sciences, Cambridge Enterprise
Tony Hickson, Managing Director, Tech Transfer, Imperial Innovations
Anne Lane, Executive Director, UCL Business
Paul van Dun, General Manager, KU Leuven Research and Development
Adam Stoten, Head, Tech Transfer, Life Sciences, Oxford University Innovation
Isobel Finnie, UK and EU Patent Attorney, Haseltine Lake

2.25 Strengthening UK and EU seed funding

We invite representation from a number of prominent UK and European seed funds to discuss the dynamic that presently exists across Europe and debate what it will take to create a EU seed capital market.

Moderator: Savvas Neophytou, Head of Life Sciences, Deepbridge Capital
Christina Takke, Co-Founder and Managing Director, V-Bio Ventures
Viktor Drvota, CIO, Karolinska Development
Michael Brandkamp, Managing Director, High-Tech Gründerfonds
Søren Møller, Managing Investment Director, Novo Seeds

3.05 Pharma's evolving role in early stage collaborations

We invite a selection of Europe's leading pharma innovation Heads to discuss and debate the evolving dynamic and role that pharma play in early stage finance and collaborations across the continent.

Moderator: Adrian Dawkes, Managing Director, PharmaVentures Ltd
Tim Luker, Director of External Innovation for Global External R&D, Eli Lilly & Co.
Nathalie ter Wengel, Senior Director, External R&D Innovation, Worldwide R&D
Michel de Baar, Executive Director, Business Development, Early Stage Search & Evaluation, Infectious Disease Europe, MSD

EARLY / GROWTH-STAGE

BROADGATE 2

1.45 Neil Darkes, Co-CEO,
Biotech and Money

Track Host

JAG SHAW
BAKER

EXCELLENCE
INNOVATION
GROWTH

1.45 Corporate venture & impact investment reimagined

We invite UK and EU Executives from the most active corporate venture arms to discuss the evolving nature of their role in funding and supporting early and growth stage companies.

Moderator: Deborah Harland, Partner, SR-One
Jeanne Bolger, VP, Venture Investments, JJDC
Roel Bulthuis, Managing Director, Merck Ventures
Johnston Erwin, Vice President, Corporate Business Development, Eli Lilly & Co.
Carolyn E Green, Executive Director, Strategic Investments, Pfizer Worldwide R&D, ERDI

2.25 EU venture financing environment

We invite UK, EU and US venture fund Executives to host an open and frank debate on the continued influence of venture capital on the sector and their appetite for growth and follow-on investments in the UK and EU.

Moderator: Adam Kostyál, Senior Vice President, Listing Services, Europe, Nasdaq
Edward van Wezel, Managing Partner, BioGeneration Ventures
Francesco de Rubertis, Partner, Medicxi
Genghis Lloyd-Harris, Partner, Abingworth
Antoine Papiernik, Managing Partner, Sofinnova Partners

3.05 The rise of the Family Office in life sciences

We invite a selection of leading Family Offices and advisory executives to discuss the turning tide of high net worths willing to invest in promising life science and medical technology.

Moderator: James Shaw, Co-Founder and Partner, JAG Shaw Baker
Chris Donegan, Managing Director, Invention Capital Associates
Dan Farrell, Chairman & CEO, Privos Capital, Multi-Family Office (MFO)
Roberto Barzi, Managing Director, Fort Rock Capital
Bence Katai, Partner, BXR Partners

CEO FORUM

BISHOPSGATE SUITE

1.45

HealthEx MedtEx
CEO FORUM CEO FORUM

The **second 2hr session** will allow talks and case studies to be presented and peer-reviewed by the group, enabling executives to learn from best practice and successful approaches.

TALKS AND CASE STUDIES

1. Investment Banking Outlook
2. PsiOxus Therapeutics - BMS Licensing Agreement
3. Nasdaq - US Public Listing

Presenters and Moderators:

Gil Bar-Nahum, Managing Director, Global Healthcare, Jefferies
Gary Green, Corporate Partner and Head of Global Equity Capital Markets, CMS Cameron McKenna
Asaf Homossany, Managing Director, EMEA, Nasdaq

3.45

AFTERNOON REFRESHMENTS

4.15 Spotlight on Medicines Discovery Catapult

The Medicines Discovery Catapult has been established as a private sector, industry focused, independent organisation to develop new approaches for the discovery and early development of new medicines helping to transform ideas into commercial products and services.

The MDC will develop and validate new ways of discovering new medicines and supporting the key UK strength in pharmaceutical, biotechnology and contract research organisations.

Chris Molloy, CEO, Medicines Discovery Catapult

4.35 Attracting China's start-up and growth funding

We invite a panel of Chinese investment Executives and industry stakeholders to discuss why China's start-up funding is heading to the UK and what we can expect to see from what many are saying is a golden age of UK-China cooperation.

Moderator: John Hodgson, Data Editor, Pharma, SCRIP Intelligence
Jiansheng Du, Life Science Specialist, Department for International Trade
Simon Haworth, Founder and CEO, Dynasty Bio and Sino-UK Fund
Rob Scott, Director, China BlueSky Partners and Investment Director (China), Bio Capital Impact Fund

5.15 Crossover and alternative investment groups

We invite prominent vc / crossover funds to discuss their strategies and appetites towards VIPes and 'top-up' financing to both IPO-ready and IPO'd companies. Plus discuss the benefits their approach brings to the corporates themselves.

Moderator: James Shaw, Co-Founder and Partner, JAG Shaw Baker
Chau Khuong, Private Equity Partner, Orbimed
Chandra Leo, Partner and Investment Advisor, HBM Partners

4.15 Inv€stable

CEOs from the UK and Europe's most progressive drug discovery, development and tool companies take to the podium to pitch their company and research to qualified investors and pharma BD&L heads.

7 companies will present for 15mins inc. Q&A.

Peter Pack, CEO, Crescendo Biologics



Alan Walker, CEO, Ryboquin



Manuel Llobet, CEO, Allergy Therapeutics



Aram Mangasarian, CEO, Noxxon Pharma



Neil Miller, CEO, Auspherix



Scott Robinson, Founder and CSO, MicroQuin



Luc Dochez, CEO, Tusk Therapeutics



4.15



The **third 1hr 45mins session** will be split into 3 sections.

The first **45mins** will allow intimate, 6-8 person roundtable discussions between the group of executives.

ROUNDTABLE TOPICS

The themes will be crowdsourced from the Executives themselves in the previous session. Executives will then be allocated their own small roundtable group in which to debate and discuss their issues.

GROUP FEEDBACK

Following the discussion, **30mins** will be allocated to allow all groups to feed back their individual learnings at the end of the session.

OUTCOMES

The final **30mins** will be used to agree upon tangible outcomes and deliverables to progress the forum for the next CEO Forum in September.

Moderator:

Chris Moore, EMEA Life Sciences Lead Partner, EY

6.00

NETWORKING DRINKS RECEPTION

Investors who have registered for the Investor Dinner at Andaz London Hotel, you will be directed from the conference venue at 7.15pm.





*Hong Hu, Research Advisor,
Lilly Research Laboratories*

It begins with a promise to discover medicines that make life better.

Since 1876, we have worked tirelessly to develop and deliver trusted medicines that meet real needs, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

To find out more about our promise, visit www.lilly.com/about.

2016 CA Approved for External Use PRINTED IN USA ©2016, Eli Lilly and Company. ALL RIGHTS RESERVED.

Lilly

The Medicines Discovery Catapult

The new national,
independent centre of
expertise for the discovery
and proof of new medicines

- Building partnerships
- Removing bottlenecks
- De-risking investments
- Finding Fast to Patient Solutions

*We will support the UK's strong
biopharma sector by creating
innovative new collaborations
with medical research charities,
technologists, venture capital
funders, regulators and
translational academics to bring
more medicines into clinical trials.*

***We are here to help the UK remain
a world-leader in drug discovery.***

If you want to find out more about our work visit md.catapult.org.uk

or contact us on: info@md.catapult.org.uk

You can also follow us at: [@MedDiscCat](https://twitter.com/MedDiscCat)



8.30

REGISTRATION AND BREAKFAST



BROADGATE 2

9.00

WELCOME

Neil Darkes, Co-CEO, Biotech and Money

9.10

'ANATOMY OF A...' PRIVATE FINANCE RAISE

We invite Executives from UK and EU life science companies that have recently concluded successful private finance raises to share their war stories, KSFs and opinions on current venture fund appetite.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: Joe Pillman, Strategic Business Consultant, JAG Shaw Baker

Nicholas Benedict, CEO, Allegra Therapeutics

Niall Martin, CEO, Artios Pharma

Robert Tansley, Investment Director, Healthcare, Cambridge Innovation Capital

Luc Dochez, CEO, Tusk Therapeutics

9.50

'ANATOMY OF AN...' INNOVATIVE DEAL STRUCTURE

We invite Executives from UK and EU life science companies that have recently conducted successful deals to share their war stories, KSFs and opinions on the deal making environment.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: Philip Broke, Partner, White & Case

Thomas Taapken, CFO, Medigene

Peter Pack, CEO, Crescendo Biologics

Cord Dohrman, CSO, Evotec

Ray Barlow, Executive Director, Corporate Development, Amgen

Phil L'Huillier, Director of Business Management, Cancer Research Technology

10.30

'ANATOMY OF AN...' EQUITY CROWDFUND

We invite a leading Crowdfunding platform and a corporate that has been successful in raising and closing financing rounds to share their war stories, KSFs and best practice to securing the desired outcome.

Goncalo de Vasconcelos, Co-Founder and CEO, SyndicateRoom

10.50

MORNING REFRESHMENTS, 1-2-1 PARTNERING AND NETWORKING



BROADGATE 1

9.00

WELCOME

Matt Pullan, SVP, BD, Biotech and Money

9.10

MEDTECH COMMERCIAL LEADERS KEYNOTE PANEL

We invite a mix of EU and US commercial leaders from large and mid-sized global corporates in medtech to discuss how they see the medtech industry evolving, their investment role in this evolution, what is attracting their attention and how are investments being structured.

Moderator: Brian Lovatt, CEO, Vision Healthcare Consultancy

Zeev Zehavi, VP, Venture Investments, Medical Devices, JJDC

David Neustaedter, VP, Venture Capital, Medtronic

Jonathan Goldstein, Director, Corporate Research and Ventures, Boston Scientific Ventures

Andreas Wuepper, Director Investments Europe, Fresenius Medical Care Ventures

Assaf Barnea, CEO, Sanara Ventures

10.00

MEDTECH INTENT: KEYNOTE INVESTOR PANEL

We invite a mix of active UK, EU and US venture capital and funds in medtech to discuss the range of sources of funding and investment open to medtech and medical device companies, and what they are looking for in an investable business

Moderator: Madeleine Armstrong, Reporter, EP Vantage

Daniel O'Mahony, Partner, Seroba Life Sciences

Peter Dines, Investment Director, Mercia Technologies

Christoph Ruedig, Partner, Albion Ventures

Josep Sanfeliu, Co-Founder and Managing Partner, Ysios Capital Partners

Rainer Strohmeier, General Partner, Wellington Partners

Anne Portwich, Partner, LSP

8.30

REGISTRATION AND BREAKFAST



WELCOME

Terry O'Dwyer, Co-CEO, Biotech and Money

9.00

9.10

Inv€stable

CEOs from the UK and Europe's most progressive drug discovery, development and tool companies take to the podium to pitch their company and research to qualified investors and pharma BD&L heads.

Companies will present for 15mins inc. Q&A.

Gregg Sando, CEO, Cell Medica



Thomas Taapken, CFO, Medigene



Ted Fjällman, CEO, Prokarium



Tim Dyer, CEO, Addex Therapeutics



Robert Scoffin, CEO, Cresset



Rainer Lichtenberger, CEO, Atriva Therapeutics



WELCOME

Josh Dance, SVP, Biotech and Money

9.10

9.10

Inv€stable

CEOs from the UK and Europe's most progressive medtech and device companies take to the podium to pitch their company and technology to qualified investors and pharma BD&L heads.

Companies will present for 15 mins inc. Q&A.

Peter Crosby, CEO, Mainstay Medical



Martin Frost, CEO, Cambridge Medical Robotics



Peter Hoyer, CCO, Quanta Dialysis Technologies



Kam Pooni, CEO, Glyconics



Federico Bürsgens, Managing Director, GNA Biosolutions



Andy Anderson, CEO, Oxford Impedance Diagnostics



BISHOPSGATE 1

BISHOPSGATE 2

10.40

MORNING REFRESHMENTS, 1-2-1 PARTNERING AND NETWORKING

11.20 'Anatomy of an...' acquisition / asset acquirer

We invite Executives from UK and EU life science companies that have recently completed acquisitions to share their war stories, KSFs and rationale on heading down the acquisition route.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: Adrian Dawkes, Managing Director, PharmaVentures Ltd
Gregg Sando, CEO, Cell Medica
Huw Jones, CEO, Chronos Therapeutics
Malcolm Weir, CEO, Heptares
Rob de Ree, Operating Partner, BioGeneration Ventures

12.00 'Anatomy of a...' debt finance

We invite Executives from UK and EU life science companies that have benefitted from issuing convertible bonds to share their approaches, KSFs and how their experiences could pave the way for other companies looking for alternative finance.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: Nooman Haque, Director of Healthcare & Life Sciences (TBC)
Edwin Moses, CEO, Ablynx
James Kuo, CEO, FIT Biotech

12.40 'Anatomy of an...' Initial Public Offering

We invite Executives from UK and EU life science companies that have concluded successful public listings to share their war stories, KSFs and opinions on current public market investor appetite.

Plus, what we can expect from the companies themselves in the coming year.

Moderator: Lisa Urquhart, Editor, EP Vantage
Joao Andrade, Group CEO, WideCells Group plc
Eduardo Bravo, CEO, TiGenix
Asaf Homossany, Managing Director, EMEA, Nasdaq

11.20 'Anatomy of a...' Medtech private finance raise

We invite Executives from medtech and digital health companies that have concluded successful private finance raises to share their war stories, KSFs and opinions on current venture fund appetite.

Moderator: Elizabeth Cairns, Medtech Reporter, EP Vantage
Alexander Schmitz, Investment Director, Endeavour Vision
Vijay Barathan, Life Science Partner GM&C Life Sciences Fund, Catapult Ventures
David Holbrook, Investment Director, Cambridge Enterprise and Venture Partner, MTI Ventures
Martin Frost, CEO, Cambridge Medical Robotics
Adam Kelliher, CEO, Avita Medical

12.00 'Anatomy of...' medtech commercialisation

We invite Executives from medtech companies that have successfully built and commercialised companies to share their war stories, KSFs and the strategies companies should pursue in the quest for growth.

Moderator: Tina Tan, Editor in Chief, Medtech Insight
Peter Hoyer, CCO, Quanta Dialysis Technologies
Peter Crosby, CEO, Mainstay Medical
Berwyn Clarke, Chairman, PBD Biotech
Alan Edwards, Chairman, ESP Technology, Asep Healthcare and Non-Exec Director, Stent Tek

12.40 'Anatomy of a...' strong, healthy valuation

We invite Executives from medtech companies that continue to post strong growth, healthy market valuations and a solid track record to share their thoughts on why the medtech sector is likely to be the most attractive to private and AIM investors over the next 12 months.

Moderator: Gary Green, Corporate Partner and Head of Global Equity Capital Markets, CMS Cameron McKenna
Charles Spicer, Chairman, 11 Health & Technologies and Creo Medical
Chas Taylor, CEO, Veryan Medical
Nissim Darvish, Senior Managing Director, OrbiMed Advisors

11.20 Inv€stable

Charles Woler, President of the Board, NovellusDx



Yochi Slonim, CEO, Anima Biotech



Anima Biotech

Pekka Mattila, CEO, Desentum



Martin Amark, CEO, Xbrane



Troels Jordansen, Chairman, Glycostem



Andy McElroy, CEO, TRN



Morten Persson, CEO, Curasight



Aidan Courtney, CEO, Censo Biotechnologies



11.20 Inv€stable

Bill Mullen, CEO, Momentum Bioscience



Adam Christie, CEO, Calcivis



Lorenzo Pradella, Co-Founder & CEO, Greenbone Ortho



Chris Ball, CEO, Jupiter Diagnostics



Bill Allan, CEO, SurgaColl Technologies



Sameer Kothari, CEO, Zilico Ltd.



Christopher Getley, Executive Chairman, AgPlus Diagnostics



Kaisa Helminen, CEO, Fimmic Oy



2.20

**'Anatomy of a...':
M&A and exit**

We invite prominent Executives from UK and EU biotech, pharma and Investment Banks to outline their thoughts and views on M&A, trade sale appetite and market forces affecting this dynamic in 2017.

Moderator: John Hodgson, Data Editor, Pharma, SCRIP Intelligence
Tim Edwards, Former Chairman, Atopix Therapeutics
Lucas de Breed, Director, INKEF Capital
Alex Leech, CEO, Creabilis

2.20

**'Anatomy of a...'
medtech IPO and
public raises**

We invite Executives from medtech companies that have concluded successful public and private finance raises to share their war stories, KSFs and what it takes to get an IPO away in today's climate.

Moderator: Philip Broke, Partner, White & Case
Achim Plum, CCO, Curetis
Sophie Baratte, CEO, Cellnovo
Simon Hubbert, CEO, Lombard Medical

2.20

Inv€stable

Claus Marquardt, Managing Director, RD-Support



David Tuch, CEO, Lightpoint Medical



James Garvin, CEO, CytoBioscience



3.00

**Healthcare outlook;
what's hot and what's not**

We invite leading life science and healthcare Analysts to share their views on what are the trends driving investment and wider opportunities, what therapeutic areas are attracting the most attention and what predictions are Analysts making for the next 12 months.

Moderator: Sam Fazeli, Head of European Research, Pharmaceuticals Analyst, Bloomberg Intelligence
Paul Cuddon, Director, Healthcare Equity Research, Numis Securities
Julie Simmonds, Director, Equity Research, Panmure Gordon
Max Herrmann, Managing Director, Stifel
Amy Walker, Partner, Healthcare Equity Research Analyst, Peel Hunt

3.00

**Medtech outlook;
what's hot and
what's not**

We invite leading Medtech Analysts to share their views on what are the trends driving investment and wider opportunities, what device areas are attracting the most attention and what predictions are Analysts making for the next 12 months.

Moderator: Tina Tan, Editor in Chief, Medtech Insight
Michael King, Medical Technology Research Analyst, Rx Securities
Mick Cooper, Healthcare and Life Sciences Analyst, Trinity Delta

2.20

Inv€stable

Ian Quirk, CEO, Active Needle Technology



Edward Bruce-White, CEO, Combat Medical



Sorin Popa, CEO, Stent-Tek



Inv€\$table

**YOUR ONSITE GUIDE TO THE 40+
DRUG DISCOVERY & DEVELOPMENT,
MEDTECH AND MEDICAL DEVICE
INV€\$TABLE SHOWCASES**





Presenter: Ian Quirk, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 2.20pm, Wednesday 8th

Market/Technology:

Address the universal problem of needle placement errors in ultrasound-guided needle interventional procedures.

Ownership: Private
URL: www.activeneedle.com



Presenter: Tim Dyer, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 9.55am, Wednesday 8th

Market/Disease Indication:

Focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders

Ownership: Public, SWX: ADXN
URL: www.addextherapeutics.com



Presenter: Christopher Getley, Executive Chairman
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 12.50pm, Wednesday 8th

Market/Technology:

A diagnostic platform that will deliver against the demanding market requirements of a true quantitative PoC, across a wide range of clinical applications.

Ownership: Private
URL: www.agplusdiagnostics.com



Presenter: Manuel Llobet, CEO
Track: Biotech Inv€\$table
Room: Broadgate 1
Time: 4.45pm, Tuesday 7th
Market/Disease Indication: Prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy).

Ownership: Public, LON: AGY
URL: www.allergytherapeutics.com



Presenter: Yochi Slonim, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 11.35am, Wednesday 8th
Market/Disease Indication: Pioneering Translation Control Therapeutics, a new class of drugs that control protein translation. Our novel drug discovery platform enables a new therapeutic strategy to approach hard / undruggable protein targets.
Ownership: Private
URL: www.animabiotech.com



Presenter: Rainer Lichtenberger, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 10.25am, Wednesday 8th

Market/Disease Indication:

Repurposing existing so-called MEK-inhibitors. First-in-class inhibitors against seasonal and pandemic influenza.

Ownership: Private
URL: www.atriva-therapeutics.com



Presenter: Neil Miller, CSO
Track: Biotech Inv€\$table
Room: Broadgate 1
Time: 5.15pm, Tuesday 7th
Market/Disease Indication: Anti-infectives company that developing a novel class of organogold-based antibiotics, designed to help address the worldwide healthcare crisis of AMR.

Ownership: Private
URL: www.auspherix.com



Presenter: Adam Christie, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 11.35am, Wednesday 8th

Market/Technology:

The CALCIVIS dental imaging system uniquely allows the live visualisation of active tooth demineralisation, enabling a new standard of preventive care in dentistry.

Ownership: Private
URL: www.calcivis.com



Presenter: Martin Frost, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 9.25am, Wednesday 8th

Market/Technology:

Cambridge Medical Robotics is a fast growing technology company developing a break-through platform solution for robotic keyhole surgery.

Ownership: Private
URL: www.cmedrobotics.com



Presenter: Gregg Sando, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 9.10am, Wednesday 8th
Market/Disease Indication:
Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Ownership: Private
URL: www.cellmedica.co.uk



Presenter: Aidan Courtney, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 1.05pm, Wednesday 8th
Market/Disease Indication:
Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking.

Ownership: Private
URL: www.censobio.com



Presenter: Edward Bruce-White, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 2.35pm, Wednesday 8th
Market/Technology:
Multi-patented, hyperthermic, cancer treatment delivery systems for the bladder and various organs within the peritoneal cavity. Enhancing delivery & increasing efficacy of existing & new drugs in cancers.

Ownership: Private
URL: www.hiveec.co.uk



Presenter: Peter Pack, CEO
Track: Biotech Inv€\$table
Room: Broadgate 1
Time: 4.15pm, Tuesday 7th
Market/Disease Indication:
Crescendo Biologics is a biopharmaceutical company discovering and developing differentiated, multifunctional Humabody® therapeutics in Oncology.

Ownership: Private
URL: www.crescendobiologics.com



Presenter: Robert Scoffin, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 10.10am, Wednesday 8th

Market/Disease Indication:
Cresset provides outstanding contract research services for molecule discovery, optimisation and supply.

Ownership: Private
URL: www.cresset-group.com




Presenter: Morten Persson, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 12.50pm, Wednesday 8th

Market/Disease Indication:
Curasight is a pioneer in the field of exploiting a novel PET imaging target - the urokinase-type plasminogen activator receptor (uPAR) - for improved breast cancer diagnose.
Ownership: Private
URL: www.curasight.com



Presenter: James Garvin, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 1
Time: 2.50pm, Wednesday 8th
Market/Technology:
Bioscience, nanoscience microchip development, algorithms and engineering to develop and manufacture instrumentation that supports ion channel research and new approaches to disease analysis and individualised treatment modalities.
Ownership: Private
URL: www.cytocentrics.com



Presenter: Pekka Mattila, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 11.50am, Wednesday 8th
Market/Disease Indication:
A research-oriented biopharmaceutical company specialised in developing novel types of allergen immunotherapy products.
Ownership: Private
URL: www.desentum.fi



Presenter: Kaisa Helminen, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 1.05pm, Wednesday 8th
Market/Technology:
Using Deep Learning AI and cloud computing, Fimmic's WebMicroscope Software brings fast and accurate diagnostics support to medical microscopy, removing slow, manual and inconsistent workflow.
Ownership: Private
URL: www.webmicroscope.com



Presenter: Kam Pooni, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 9.55am, Wednesday 8th

Market/Technology:

Solutions to the definitive diagnosis of COPD and the early identification of exacerbation. A valuable tool for the design and implementation of novel COPD therapeutic interventions.

Ownership: Private
URL: www.glyconics.com



Presenter: Troels Jordansen, Chairman
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 12.20pm, Wednesday 8th
Market/Disease Indication:
 An innovator in allogeneic cellular immunotherapy using Natural Killer (NK) cells - oNKord® - or antigen presenting cells - sDCord® - for treatment of leukemia, lymphoma, solid tumors.
Ownership: Private
URL: www.glycostem.com



Presenter: Federico Bürsgens, Managing Director
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 10.10am, Wednesday 8th

Market/Technology:

Instruments, OEM modules, and assays for ultra-fast, molecular pathogen detection using our breakthrough technology: Laser PCR.

Ownership: Private
URL: www.gna-bio.com



Presenter: Lorenzo Pradella, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 11.50am, Wednesday 8th

Market/Technology:

Developing a highly innovative, bone regenerating, load-bearing implants to treat severe fractures and conditions such as trauma and tumours that result in extensive bone loss.

Ownership: Private
URL: www.greenbone.it



Presenter: Chris Ball, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 12.05pm, Wednesday 8th

Market/Technology:

Unlike traditional blood testing solutions, our technology offers a more accessible and faster way to get reliable blood results.

Ownership: Private
URL: www.jupiterdiagnostics.com



Presenter: David Tuch, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 1
Time: 2.35pm, Wednesday 8th

Market/Technology:

The company's molecular imaging technology, based on Cerenkov Luminescence Imaging, has the potential to detect cancer in real-time during surgery, providing more accurate cancer treatment while sparing healthy tissue.

Ownership: Private
URL: www.lightpointmedical.com



Presenter: Peter Crosby, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 9.10am, Wednesday 8th
Market/Technology:
 A European medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8, for people with disabling Chronic Low Back Pain.
Ownership: Public, MSTY.IE and MSTY.PA
URL: www.mainstay-medical.com



Presenter: Thomas Taapken, CFO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 9.25am, Wednesday 8th
Market/Disease Indication:
 The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development.
Ownership: Public, ETR: MDG1
URL: www.medigene.com



Presenter: Scott Robinson, CEO
Track: Biotech Inv€\$table
Room: Broadgate 1
Time: 5.30pm, Tuesday 7th
Market/Disease Indication:
 MicroQuin is a biotechnology, R&D based company. We currently focus on developing therapeutics to address a range of oncological disease.
Ownership: Private
URL: www.microquin.com



Presenter: Bill Mullen, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 11.20am, Wednesday 8th

Market/Technology:

A range of innovative diagnostic products to help combat antibiotic resistance and sepsis by providing early detection of the presence and absence of bloodstream infections.

Ownership: Private
URL: www.momentumbio.co.uk



Presenter: Charles Woler, President of the Board
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 11.20am, Wednesday 8th
Market/Disease Indication: NovellusDx provides comprehensive, fully-automated, functional gene profiling of individual patient tumors including charting the full landscape of known and unknown mutations.
Ownership: Private
URL: www.novellusdx.com



Presenter: Aram Mangasarian, CEO
Track: Biotech Inv€\$table
Room: Broadgate 1
Time: 5.00pm, Tuesday 7th
Market/Disease Indication: Core focus is on cancer treatment. NOXXON is using its proprietary class of drugs called Spiegelmers* to target the tumor microenvironment, a new frontier in cancer treatment.
Ownership: Public, EPA: ALNOX
URL: www.noxxon.com



Presenter: Andy Anderson, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 10.25am, Wednesday 8th

Market/Technology:

Researches, designs and will market diagnostic tests for the measurement of clinical bio markers that reduce healthcare costs and improve patient outcomes.

Ownership: Private
URL: www.oxfordimpedence.com



Presenter: Ted Fjällman, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 9.40am, Wednesday 8th

Market/Disease Indication:

Prokarium develops oral vaccines against C.diff, exacerbations of COPD/asthma, Chlamydia, and under a UK government contract a plague vaccine.

Ownership: Private
URL: www.prokarium.com



Presenter: John Milad, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 9.40am, Wednesday 8th

Market/Technology:

Quanta, a pioneering medical devices company, has developed advanced haemodialysis systems for use in the home and clinic.

Ownership: Private
URL: www.quanttdt.com



Presenter: Claus Marquardt, MD
Track: Medtech Inv€\$table
Room: Bishopsgate 1
Time: 2.20pm, Wednesday 8th

Market/Technology:

Global supplier of bespoke lab-on-a-chip development services and owner of world's only direct, fast, reliable and cheap graphene layer manufacturing process on any surface.

Ownership: Private
URL: www.rd-support.eu



Presenter: Alan Walker, CEO
Track: Biotech Inv€\$table
Room: Broadgate 1
Time: 4.30pm, Tuesday 7th
Market/Disease Indication:

We use our expertise to turn under-developed intellectual property ideas into viable commercial realities. Focused on commercialising patented technologies in the area of human cancer medicine.

Ownership: Private
URL: www.ryboquin.co.uk



Presenter: Sorin Popa, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 2.50pm, Wednesday 8th

Market/Technology:

Stent Tek is developing a novel catheter based system that provides a better way for patients to receive haemodialysis (HD) for kidney failure.

Ownership: Private
URL: www.stent-tek.com



Presenter: Bill Allan, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 12.20pm, Wednesday 8th

Market/Technology:
A medical devices company, develops novel tissue regeneration products for the surgical treatment of disease of bone, cartilage, and other human tissue.

Ownership: Private
URL: www.surgacoll.com



Presenter: Andy McElroy, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 12.35pm, Tuesday 7th
Market/Disease Indication:
EmstoPA, a humanised antibody fragment for treatment of bleeding complications in patients who have received the clot buster tPA (Activase® , Alteplase). tPA is used in conditions caused by blood clots; strokes and pulmonary embolism.
Ownership: Private
URL: www.trn.net



Presenter: Luc Dochez, CEO
Track: Biotech Inv€\$table
Room: Broadgate 1
Time: 5.45pm, Tuesday 7th
Market/Disease Indication:
Tusk Therapeutics is harnessing the power of the innate immune system to fight cancer through the development of novel immune modulating therapeutics.
Ownership: Private
URL: www.tusktherapeutics.com



Presenter: Martin Amark, CEO
Track: Biotech Inv€\$table
Room: Bishopsgate 1
Time: 12.05pm, Wednesday 8th

Market/Disease Indication:
Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables.

Ownership: Public, NASDAQ
URL: www.xbrane.com



Presenter: Sameer Kothari, CEO
Track: Medtech Inv€\$table
Room: Bishopsgate 2
Time: 12.35pm, Wednesday 8th
MarketTechnology:
Zilico's first product, ZedScan, is already making significant impact within the cervical cancer diagnostic pathway. Zilico is also developing other real-time diagnostic devices for oral, anal & oesophageal cancers.
Ownership: Private
URL: www.zilico.co.uk

GET INVOLVED AND SHOWCASE YOUR COMPANY AT A FUTURE EVENT

Our mission at Biotech and Money / Medtech and Money is to connect innovative corporates with the right capital.

Inv€\$table Showcases are one of the most effective ways that we can help you promote your company or portfolio company to a global audience.

If you'd like to be considered for an Inv€\$table Showcase at either the **2nd Inv€Stival Showcase** on the 15th November 2017 or at the **4th Biotech and Money / Medtech and Money London Conference** on the 6th & 7th February 2018 then send us an email.


Contact **Josh Dance** at josh@biotechandmoney.com to reserve your 15mins showcase.

Showcases at both Inv€\$tival Showcase 2016 and Biotech and Money / Medtech and Money London 2017 were sell outs, so don't leave your enquiry too late.

ATTENDING COMPANIES (525+ ATTENDEES, 370+ COMPANIES)

4BIO Capital Partners	CytoBioscience	Kreos Capital	PharmaVentures
Abbvie	Danish Growth Capital II	KU Leuven R&D	Pharmedartis
Abingworth	Deep Knowledge Life Sciences	Kurma Partners	Pragma Therapeutics
Ablynx NV	Deep Knowledge Ventures	L1 Capital / Europe Offering	Precious Cells
Abzena	Deepbridge Capital	Lakeside Healthcare	Privos Capital
Active Needle Technology	Deepbridge Syndicate	Lakeside Plus	Prokarium
Addex Therapeutics	Deltex Medical Group	LBA Ventures	ProteoDesign
AdRem Capital	Department for International Trade	Legal & General Investment Management	Proteome Sciences
Advent Life Sciences	Desentum Oy	Levrett PLC	PsiOxus Therapeutics
Advisory London	Dievini Hopp BioTech holding GmbH & Co	Life Sciences Hub Wales	PsyOmics
Aetas Global Markets	Discuva	Life Sciences Partners	Qbtech
Aglaris Ltd.	Domainex / Canbex Therapeutics	LifeSci Advisors	Quanta Dialysis Technologies
AgPlus Diagnostics	Drais Pharmaceuticals	Lightpoint Medical	QuantuMDx Group
Alacrita	Drug Discovery Today	Lombard Medical	RBV Capital
Albion Technology & General VCT	e-consultancy	Longevity Venture Partners	RD-Support
Albion Ventures	Edesa Biotech	M-V Arterica	Redline Capital
Allecrea Therapeutics	EGB Advisors PR	Mainstay Medical Limited	ReNeuron
Allergy Therapeutics	Eli Lilly & Co.	Majid Al Futtaim Trust	ReViral
Amadeus Capital Partners	Endeavour Vision	Mann Bioinvest	Rex Bionics
Amgen	Enso Ventures	Marketing Birmingham	RMI Partners
Anima Biotech	EP Vantage	Marks & Clerk	Rosetta Capital
Apposite Capital	Epidarex	Maven Capital Partners	Rothschild & Co.
Aptamer Group	EQS	Medicine Discovery Catapult	Roundcape
Aptamer Solutions	Ergomed	Medicon SD Ltd	Ruffena Capital
Arix Bioscience	Esperante	Medicxi	RX Securities
Arthurian Life Sciences	EURASANTE	Medigene	Ryan-Kay
Artios Pharma	Evernow Publishing Ltd	MedInnovation	Ryboquin
Artios Therapeutics	Evotec	MedTech Imperial	Ryboquin Company
ASep healthcare	Exonate	Medtech Insight	Sanara Ventures
Astex Pharmaceuticals	EY	Medtronic	Saniona
Atelix	F-Prime Capital	Memcor	Scancell Holdings
Atopix Therapeutics	Family Office	Mercia Fund Managemnet	SCIAD
Atriva Therapeutics	Fimmic Oy	Mercia technologies	Scottish Equity Partners
Auspherix	Financial Times	Merck	SCRIP
Avita Medical	FIT Biotech	Merck Ventures	SCRIP Intelligence
Bactevo	Fladgate	Meyer & Co	Sensia
Barclays	Forbion Capital Partners	Microbiotix	Sentinel Oncology
Beaufort Securities	Forrest Innovations	MicroQuin	Seroba Life Sciences
Belsize Asset Management	Fort Rock Capital	Midatech Pharma	Silicon Valley Bank
Bergen Asset Management	FreeMind Group	Miotech Medpartners	Sino-UK Fund
BioCatalyst Capital Partners	Fresenius Medical Care Ventures	MIRABAUD Securities	Sixth Element Capital
BioGeneration Ventures	Galecto Biotech	Mitotech	SJB Technical Recruitment
Bionow	Gill Jennings & Every	Momentum Bioscience	Sofinnova Partners
BioPharm Insight - Mergermarket Group	Glyconics	MP.com	Solvotrin Therapeutics
BioSeed Capital	Glycostem	MRC Technology	SR-One
Biotech and Money	GNA Biosolutions	MSD	Stent-Tek
Biotech Growth Trust	GR Capital	Multipharma SA	Stevenage Bioscience Catalyst
Bloomberg	GreenBone Ortho	MVM Life Science Partners	Stifel
Boston Scientific Ventures	GTL Investments	N+1 Singer	Sunergos Innovations
Bracknor Investment Group	Hadean Ventures	Nanobiotix	Sunstone Capital
Brewin Dolphin	Harbert European Growth Capital	Narec Capital Ltd	SurgaColl Technologies
Bristows	Haseltine Lake	Nasdaq	SV Life Sciences
British Expats in Life Sciences	HBM Partners	Nature Biotechnology	Syncona
British Pharmacological Society	HealthCap	NeoMed	Syndicate Room
BROTHERS & Partners Europe	HealthCare Royalty Partners	NetScientific	Takeda Ventures, Inc. (TVI)
BWL Investments	Heptares Therapeutics	New Hope Investments	Talentmark
BXR Partners	Hermes Pacific Capital	New Mosaic Ltd	Tassi & Co.
Calcivis	High-Tech-Gruenderfonds Management	New Science Global Healthcare Fund	The Mergermarket Group
Cambridge Enterprise	Horizon Discovery	New Wave Ventures	The Pharma Letter
Cambridge Enterprise Seed Funds	IAG	Norgine Ventures Management Limited	The Research Network
Cambridge Innovation Capital	ICMBH	North-East Healthcare Investment	The SidebySide Partnership
Cambridge Medical Robotics	Ignite Capital Partners	NovellusDx	The University of Manchester
Cancer Research Technology	iMicroQ	Novo A/S	The Wellcome Trust
Capital Cell	Immupharma	Novo Ventures	Tigenix
Capital Family Office	Imperial Innovations	NOXXON Pharma	Touchstone Innovations
Capital Grand Est.	Inbio Ventures	Numis Securities Limited	Trinity Delta
Capricorn Venture Partners	Independent	O2h Ventures	Tusk Therapeutics
Carrick Therapeutics	INKEF Capital	Odgers Berndtson	TVM Capital Life Science
Catapult Ventures	Inositec	OION	TxCell
Celixir	Instinctif Partners	Oncopeptides	UBM
Cell and Gene Therapy Catapult	Intralinks	One Nucleus	UCL
Cell Medica	Inventages	Oppilotech	UCL Business
Cellnovo	Invention Capital Associates	OrbiMed	University of Southampton
Censo Biotechnologies	Investarget	OrbiMed Healthcare Fund Management	V-Bio Ventures
China BlueSky Ventures / BioCapital Impact Fund	Investec Wealth & Investment	ORI Fund	Ventac Partners
Chronos Therapeutics	Invisio	Oxford BioMedica	Veryan Medical
Citigate Dewe Rogerson	IOFIX Ltd.	Oxford Impedance Diagnostics	Vision Healthcare Consultancy
CK2 Partners Ltd	IP Group	Oxford Pharmascience	Wellcome Trust
Clinigen	Iratel Ventures	Oxford Technology	Wellington Partners
Clubb Capital	Isis Innovation	Oxford University Innovation	Westwicke Partners
CMS Cameron McKenna	J A Kemp	Oxon	White & Case
Coalesce Product Development	J&J Development Corp.	Panakes Partners	Widecells
Combat Medical	JAG Shaw Baker	Panmure Gordon & Co.	Woerwag Pharma GmbH & Co.
Cooley (UK) LLP	Jefferies	Papyrus Therapeutics	Wren Capital
Coulter Partners	Johnson & Johnson Innovation	Parkure	X-Ventures
Covington and Burling	Jordi Ho	Partners HealthCare	Xanthella
Creabilis	JP Morgan	Paul Capital	Xbrane Biopharma
CREO Medical	Julz Co	PBD Biotech	Ysios Capital
Crescendo Biologics	Jupiter Diagnostics	Peel Hunt	Yuuwa Capital
Cresset	Karolinska Development	Peptinnovate	Zilico
Curasight	King's College London	Pfizer	
Curetis	King's Health Partners & King's Commercialisation Institute	Pharma Intelligence	
		PharmaPhorum	

CONFERENCE FLOORPLAN



FLOORPLAN KEY



1-2-1 Partnering Room



Breakfast and Lunch Station



Informal Networking Points



Coffee and Tea Station



PharmaTV Camera Station



Restrooms



ASSOCIATE PARTNERS



MEDIA PARTNERS



www.biotechandmoney.com/london

Contact us:

Suite 144, The Business Design Centre, 52 Upper St, London N1 0QH

Email: info@biotechandmoney.com

Phone: +44 (0) 203 637 5908